Opposing Effects of β-Blockers and Angiotensin-Converting Enzyme Inhibitors on Development of New-Onset Diabetes Mellitus in Patients With Stable Coronary Artery Disease

Study Questions:

What is the risk of new-onset diabetes mellitus (NOD) with beta-blockers, and would angiotensin-converting enzyme (ACE) inhibition modify this risk?